<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954758</url>
  </required_header>
  <id_info>
    <org_study_id>1304-C-107-CS</org_study_id>
    <nct_id>NCT01954758</nct_id>
  </id_info>
  <brief_title>The ERA Test as a Diagnostic Guide for Personalized Embryo Transfer</brief_title>
  <official_title>Clinical Study, International, Multicentre, Prospective, Randomised, Interventional and Controlled, Comparing Fresh Embryo Transfer (ET) Versus Elective Delayed Embryo Transfer (DET) and Personalised Embryo Transfer (pET) Guided by the ERA (Endometrial Receptivity Array) Test as a Diagnostic Tool in Patients Treated by IVF/ICSI (in Vitro Fertilisation; Intra-cytoplasmic Sperm Injection)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenomix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project seeks to demonstrate the clinical value of the personalised diagnosis of the
      endometrial factor in infertility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project seeks to investigate differences in implantation (IR), pregnancy (PR), ongoing
      pregnancy (OP) rates and delivery among women undergoing transfer at the blastocyst stage in
      their first IVF/ICSI cycle comparing the normal practice of same-cycle embryo transfer in a
      fresh cycle (ET) versus deferred embryo transfer (DET) versus personalized embryo transfer
      (pET) after endometrial receptivity analysis (ERA).

      A total of 546 infertile women under 38 years old undergoing her first IVF/ICSI cycle with
      elective blastocyst transfer are randomized in this prospective, multicenter, open label and
      controlled trial. Patients are allocated through computer-generated randomization into one
      of the three groups: Fresh embryo transfer (ET), Deferred embryo transfer (DET) or
      personalized embryo transfer (pET) after identification of the personalized window of
      implantation using the ERA test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancies</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic pregnancies</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical miscarriages</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnacy rate</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetric pathologies</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late gestational miscarriages</measure>
    <time_frame>40 weeks</time_frame>
    <description>Miscarriages after the second and third trimester</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">546</enrollment>
  <condition>Endometrial Receptivity</condition>
  <arm_group>
    <arm_group_label>Arm C-R: pET (ERA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and will undergo an endometrial biopsy in this substituted cycle after five days (around 120 hours) of progesterone administration. The ERA test will analyze the endometrial receptivity to determine the most suitable time (the most receptive stage) for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, if a receptive profile was previously demonstrated by the ERA test, a personalized embryo transfer (pET) will be performed following the same conditions in which the ERA test was obtained using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm CNR: pET (ERA+ERA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and will undergo an endometrial biopsy in this substituted cycle after five days (around 120 hours) of progesterone administration.The ERA test will analyze the endometrial receptivity to determine the most suitable time (the most receptive stage) for the embryo transfer. If the window of implantation (WOI) is displaced (profile non receptive), a new biopsy will be taken on a different day based on the result of the first ERA test to identify the personalized WOI. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified.In a subsequent cycle, a personalized embryo transfer (pET) will take place according to the second ERA test result. A pET using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage) will be performed following the same conditions as in the second ERA test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A: Fresh embryo transfer (ET)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Deferred embryo transfer (DET)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), an elective deferred embryo transfer (DET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresh Embryo Transfer (ET)</intervention_name>
    <arm_group_label>Arm A: Fresh embryo transfer (ET)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Deferred Embryo Transfer (DET)</intervention_name>
    <arm_group_label>Arm B: Deferred embryo transfer (DET)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>personalized Embryo Transfer (pET)</intervention_name>
    <arm_group_label>Arm C-R: pET (ERA)</arm_group_label>
    <arm_group_label>Arm CNR: pET (ERA+ERA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients indicated to undergo a cycle of IVF/ICSI with their own oocytes.

          2. Age ≤ 37 years

          3. BMI: 18.5 to 30

          4. Normal ovarian reserve (AFC ≥ 8; FSH &lt; 8)

          5. The most appropriate stimulation protocol will be decided by their doctor.

          6. Blastocyst transfer (on day 5 or 6)

          7. Blastocyst vitrification with open protocols (Cryotop, Cryoleaf, or Cryolock) or
             closed protocols (Cryotip or CBSStraw.)

          8. Any pathology affecting the endometrial cavity such as polyps/sub-mucosal myomas,
             intramural myomas &gt; 4 cm, or hydrosalpinx affecting the endometrial cavity must be
             previously operated.

        Exclusion Criteria:

          1. Patients with repeated miscarriages (&gt; 2 previous biochemical pregnancies or &gt; 2
             spontaneous miscarriages)

          2. Patients with a severe male factor (spermatozoa &lt; 2 million/ml)

          3. Patients with implantation failure (&gt;3 failed cycles with good quality embryos)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Simon, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Valencia / Igenomix</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Gomez, BSc MSc</last_name>
    <phone>+34963905310</phone>
    <phone_ext>11543</phone_ext>
    <email>carlos.gomez@igenomix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Valbuena, MDPhD</last_name>
    <phone>+34963905310</phone>
    <phone_ext>18544</phone_ext>
    <email>diana.valbuena@igenomix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Westphal, MDPhD</last_name>
      <phone>650-498-7317</phone>
      <email>lynnw@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Lynn Westphal, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre of Reproductive Medicine UZ Brussles</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Nulens, BSc</last_name>
      <phone>3224776699</phone>
      <email>elsie.nulens@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Shari Mackens, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Infertilidade e Medicina Fetal do Norte Fluminence</name>
      <address>
        <city>Campos dos Goytacazes</city>
        <state>Rio de Janeiro</state>
        <zip>28035-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Augusto Colucci Coelho, MDPhD</last_name>
      <phone>552227231277</phone>
      <email>guto.colucci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Augusto Colucci Coelho, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Reproduçao Humana Nilo Frantz</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Del Sur</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Pagnoncelli, BSc</last_name>
      <phone>555133284680</phone>
      <email>embriologistas@nilofrantz.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Marcos Iuri Roos Kulmann, BSc</last_name>
      <phone>555133284680</phone>
      <email>kulmannmarcos@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Norma Pagnoncelli, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Embriofert Clínica Medica Hospitalar Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01401-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edson Borges, MDPhD</last_name>
      <phone>551130188181</phone>
      <email>edson@fertility.com.br</email>
    </contact>
    <investigator>
      <last_name>Edson Borges, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntington Medicina Reproductiva</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04501-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Bonetti, BSc</last_name>
      <phone>5511984813107</phone>
      <email>tatibonetti76@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Leme Alves da Motta, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Reprodução Governador Mario Covas</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Serafini, MDPhD</last_name>
      <email>pserafini@huntington.com.br</email>
    </contact>
    <investigator>
      <last_name>Paulo Serafini, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sofia Hospital of Reproductive Medicine - SBALAGRM</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Krumov, MD</last_name>
      <phone>35924391929</phone>
      <email>vladimirov@ivf.bg</email>
    </contact>
    <investigator>
      <last_name>Iavor Vladimirov, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oak Clinic Sumiyoshi</name>
      <address>
        <city>Osaka</city>
        <zip>557-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Young, BSc</last_name>
      <phone>0643981000</phone>
      <email>kate_y@oakclinic-group.com</email>
    </contact>
    <contact_backup>
      <last_name>Dustin Spillers, BSc</last_name>
      <phone>0643981000</phone>
      <email>spillers_dj@oakclinic-group.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sagiri Taguchi, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IECH Centro de Fertilidad</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Castañeda, MD</last_name>
      <phone>528183471888</phone>
      <email>alfonsogcastanedal@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Ashanti Aguilar, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Vida Matamoros</name>
      <address>
        <city>Matamoros</city>
        <state>Tamaulipas</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alma Cepeda, BScPhD</last_name>
      <phone>528688162625</phone>
      <email>almacepeda@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Arturo Garza, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Panama</name>
      <address>
        <city>Panama</city>
        <zip>0819</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saul Barrera, MDPhD</last_name>
      <phone>5072125484</phone>
      <email>saul.barrera@ivi.es</email>
    </contact>
    <contact_backup>
      <last_name>Roberto Epifanio, MDPhD</last_name>
      <phone>5072125484</phone>
      <email>roberto.epifanio@ivi.es</email>
    </contact_backup>
    <investigator>
      <last_name>Saul Barrera, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Ginecological Hospital</name>
      <address>
        <city>Novi Sad</city>
        <zip>210000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjana Dosic, BSc</last_name>
      <phone>38163541098</phone>
      <email>mirjana.dosic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zorica Crnogorac, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KK Women´s and Children Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Ann Khoo Su Ling, BSc</last_name>
      <phone>6562255554</phone>
      <email>charmaine.ann.khoo.sl@kkh.com.sg</email>
    </contact>
    <investigator>
      <last_name>Sadhana Nadarajah, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Bilbao</name>
      <address>
        <city>Leioa</city>
        <state>Bizkaia</state>
        <zip>48940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Quintana, BScPhD</last_name>
      <phone>34944806020</phone>
      <email>fernando.quintana@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Marcos Ferrando, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Las Palmas</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Doming, MDPhD</last_name>
      <phone>34828024300</phone>
      <email>javier.domingo@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Javier Domingo, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Madrid</name>
      <address>
        <city>Aravaca</city>
        <state>Madrid</state>
        <zip>24527</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Toribio, BSc</last_name>
      <phone>34911802900</phone>
      <email>monica.toribio@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Juan Garcia-Velasco, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agustina Ramos, BSc</last_name>
      <phone>34986021860</phone>
      <email>agustina.ramos@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Elkin Muñoz, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Ballester, BSc</last_name>
      <phone>34966012490</phone>
      <email>ana.ballester@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Muñoz, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Llorens, BSc</last_name>
      <phone>34932063000</phone>
      <email>isabel.llorens@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Gemma Castillon, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProcreaTec</name>
      <address>
        <city>Madrid</city>
        <zip>28036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Izquierdo, MDPhD</last_name>
      <phone>34914585804</phone>
      <email>alexandraizquierdo@procreatec.com</email>
    </contact>
    <investigator>
      <last_name>Lourdes Lopez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Isabel Salazar, MDPhD</last_name>
      <phone>34952061240</phone>
      <email>anabel.salazar@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Ana Isabel Salazar, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Murcia</name>
      <address>
        <city>Murcia</city>
        <zip>30007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Landeras, MDPhD</last_name>
      <phone>34968200031</phone>
      <email>jose.landeras@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Jose Landeras, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Santamaria, BSc</last_name>
      <phone>34954286274</phone>
      <email>esther.santamaria@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Fernandez, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Giles, MDPhD</last_name>
      <phone>+34963050900</phone>
      <email>juan.giles@ivi.es</email>
    </contact>
    <contact_backup>
      <last_name>Carlos Simon, MDPhD</last_name>
      <phone>+34963050900</phone>
      <email>carlos.simon@ivi.es</email>
    </contact_backup>
    <investigator>
      <last_name>Juan Giles, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IVI Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50018</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Serna, MDPhD</last_name>
      <phone>34976075082</phone>
      <email>jose.serna@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Jose Serna, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bahceci Health Group</name>
      <address>
        <city>Istanbul</city>
        <zip>34500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Necati Findikli, MDPhD</last_name>
      <phone>902123103100</phone>
      <email>necatif@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mustafa Bahceci, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Carlos Simon</investigator_full_name>
    <investigator_title>Scientific Director IGENOMIX; Gynaecologist IVI Valencia</investigator_title>
  </responsible_party>
  <keyword>Window of implantation</keyword>
  <keyword>Personalized embryo transfer</keyword>
  <keyword>Fresh embryo transfer</keyword>
  <keyword>Delayed embryo transfer</keyword>
  <keyword>Elective deferred embryo transfer</keyword>
  <keyword>Endometrial receptivity array</keyword>
  <keyword>Endometrial receptivity analysis</keyword>
  <keyword>Endometrial receptivity test</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
